Bengaluru: Carlyle-backed Indian life science technology company Indegene Ltd has filed for an initial public offering, draft papers submitted to market regulator Sebi showed on Thursday.
The IPO consists a fresh issue of shares worth Rs 950 crore and a sale of up to 36.3 million shares by existing shareholders, including a Carlyle entity, the filing showed.
A news portal said the company was aiming to raise between Rs 2,750 crore and Rs 3,000 crore through the offering.
Reuters could not immediately confirm those details. Indegene did not respond to Reuters’ request for comment.
CA Dawn Investments, a Carlyle entity which held around 46 million shares, or a 20.8% stake in the company, will be selling up to 17.2 million shares in the offering, according to the filing.
Capital, Citigroup Global Markets, J.P. Morgan India and Nomura Financial Advisory and Securities were book running lead managers to the IPO.
Related Posts
Denial of responsibility! TechnoCodex is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.
